SOFIE Biosciences to Receive Strategic Growth Investment From Trilantic North America

Paul, Weiss is advising SOFIE Biosciences, a Positron Emission Tomography (PET) radiopharmacy and contract development and manufacturing organization, in a substantial strategic growth investment made by global private equity firm Trilantic North America. Trilantic’s investment will be made in partnership with SOFIE’s founding team, who will retain a meaningful equity stake and continue to lead the business. Financial terms of the transaction were not disclosed. The transaction is expected to close later in 2024, subject to customary closing conditions and regulatory approvals.

The Paul, Weiss team is led by corporate partner Jeffrey Marell, tax partner Scott Sontag and corporate counsel Ji Lu, and includes corporate counsel Jason Tyler; executive compensation partner Jarrett Hoffman and counsel Sasha Belinkie; litigation partners Jaren Janghorbani and Aidan Synnott; intellectual property partner Claudine Meredith-Goujon; and environmental counsel William O'Brien.